Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q93075
UPID:
TATD2_HUMAN
Alternative names:
-
Alternative UPACC:
Q93075; Q3MIL9; Q5BKU0
Background:
Putative deoxyribonuclease TATDN2 plays a crucial role in DNA metabolism, facilitating the breakdown of DNA molecules. This protein's enzymatic activity is essential for maintaining genomic stability and proper cellular function.
Therapeutic significance:
Understanding the role of Putative deoxyribonuclease TATDN2 could open doors to potential therapeutic strategies. Its involvement in DNA metabolism makes it a promising target for interventions in diseases where DNA repair mechanisms are compromised.